Last reviewed · How we verify
BAT1406
BAT1406 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.
BAT1406 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity. Used for Non-small cell lung cancer, Other solid tumors (in development).
At a glance
| Generic name | BAT1406 |
|---|---|
| Also known as | No Other Intervention Names |
| Sponsor | Bio-Thera Solutions |
| Drug class | Bispecific antibody; PD-1/TGF-β inhibitor |
| Target | PD-1 and TGF-β |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By blocking PD-1, BAT1406 relieves inhibitory signals on T cells, while concurrent TGF-β neutralization further reduces immunosuppression in the tumor microenvironment. This dual mechanism aims to overcome resistance to single-agent checkpoint inhibition and enhance T-cell activation and infiltration into tumors.
Approved indications
- Non-small cell lung cancer
- Other solid tumors (in development)
Common side effects
- Immune-related adverse events (irAEs)
- Fatigue
- Infusion reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAT1406 CI brief — competitive landscape report
- BAT1406 updates RSS · CI watch RSS
- Bio-Thera Solutions portfolio CI